RBC Capital Downgrades ResMed to Sector Perform, Lowers Price Target to $202
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Craig Wong-Pan has downgraded ResMed (NYSE:RMD) from Outperform to Sector Perform and lowered the price target from $273 to $202.
October 12, 2023 | 11:55 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ResMed has been downgraded by RBC Capital from Outperform to Sector Perform, with a lowered price target from $273 to $202.
The downgrade from Outperform to Sector Perform by RBC Capital, along with a significant reduction in the price target, indicates a less optimistic outlook for ResMed. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100